By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Xeris Pharmaceuticals  

3925 West Braker Lane, Third Floor

Austin  Texas  78759  U.S.A.
Phone: 512-534-8340 Fax: n/a


SEARCH JOBS



Segment
Start Up





Company News
Xeris Pharmaceuticals To Present G-Pen Human Factors Study Results At 2016 ATTD Meeting 2/4/2016 12:15:16 PM
Xeris Pharmaceuticals Scores $41 Million Series C Financing 1/7/2016 8:53:00 AM
Xeris Pharmaceuticals Completes $17.9M Series B Round And Appoints Phillip Johnson As Chief Financial Officer 1/8/2015 7:32:19 AM
FDA And European Medicines Agency Grant Orphan Designation To Xeris Pharmaceuticals ' Soluble Glucagon For Prevention Of Hypoglycemia In Congenital Hyperinsulinism Patients 11/12/2014 10:31:58 AM
Xeris Pharmaceuticals Announces Dosing Of First Patient In Phase 2 Clinical Trial Of Its Investigational Soluble Glucagon For The Treatment Of Mild-To-Moderate Hypoglycemia 6/6/2014 8:54:40 AM
Xeris Pharmaceuticals Announces Dosing Of First Patient In Phase 2 Clinical Trial Of Its Investigational Soluble Glucagon Formulation For Pumps 4/25/2014 9:16:43 AM
Xeris Pharmaceuticals Receives U.S. Patent For Its Novel, Stable Non-Aqueous Glucagon Formulations 4/16/2014 9:19:55 AM
Xeris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation 10/18/2013 9:32:31 AM
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions 6/21/2013 9:34:35 AM
Xeris Pharmaceuticals Awarded Phase II Funding of National Institutes of Health (NIH) Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas 4/17/2013 11:18:20 AM
12
//-->